Since IL-17 has been found to play an important role in the pathogenesis of spondyloarthropathy [53], it has been shown that IL-17a monoclonal antibody is effective in the treatment of ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis without serious adverse events [54–56]. The gene discussed is IL17A; the disease is rheumatoid arthritis.